ClinicalTrials.gg
CompletedNCT00867516ALD518-003Updated Jul 9, 2020

Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis

A Phase 2 interventional study of ALD518 and Infusion without ALD518' in Arthritis, Rheumatoid, sponsored by CSL Behring. Completed at 26 sites in 6 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-07-09.

Sponsored by CSL Behring (part of CSL Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 181 studies in Arthritis, Rheumatoid with a site in Russian Federation — none open to participants now, 2 under way, 1 of them phase 3. Arthritis, Rheumatoid · Russian Federation.

Enrollment
140th of 175
127 · median 390
Started
2008
with 10 others
Phase 2
66 of 181
none open now
Registered
41st of 181
by date

Among the 181 studies in Arthritis, Rheumatoid with a site in Russian Federation, this one is the 140th largest by enrollment of the 175 interventional ones that give a count, is one of 11 that started in 2008, is one of 66 in phase 2, and was the 41st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 181 studies in Arthritis, Rheumatoid with a site in Russian Federation is open now. The open studies under Arthritis, Rheumatoid, anywhere →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 181 studies in Arthritis, Rheumatoid with a site in Russian Federation as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of ALD518 in three different doses in patients who have not had an adequate response to methotrexate.

Read the detailed description

This will be a phase II, parallel-group, double-blind, randomized, placebo-controlled study of ALD518 in patients with active RA with an inadequate response to methotrexate.

Enrolled patients will be screened within a 4-week period (Day -35 to -7). within a 12-day period (Day-14 to -3) before initial dosing on Day 1 patients will be randomized to one of the following four treatment groups:

Group A: 2x ALD518 80 mg Group B: 2x ALD518 160 mg Group C: 2x ALD518 320 mg Group D: 2x placebo

In all treatment groups patients will continue to take a stable dose of methotrexate.

There will be a total of 11 visits. The total duration of the patient study participation will be approximately 16 weeks (excluding the screening period).

03

Conditions studied

  • Arthritis, Rheumatoid
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active Rheumatoid Arthritis for at least 16 weeks duration
  • Have a C-reactive protein (CRP) of ≥ 10mg/L
  • Have a stable dose of methotrexate (≥ 10mg/week) for at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Arthritis onset prior to 16 years old
  • Received any biologic therapy in the previous 12 months
  • A history of or currently have active tuberculosis
  • Any concurrent medical condition
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    1

    ALD518 80 mg

    Biological: ALD518

  • Experimental
    2

    ALD518 160 mg

    Biological: ALD518

  • Experimental
    3

    ALD518 320 mg

    Biological: ALD518

  • Placebo comparator
    4

    No ALD518

    Biological: Infusion without ALD518'

Interventions

  • BiologicalALD518

    Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8

  • BiologicalInfusion without ALD518'

    250 cc Normal saline IV over one hour Weeks 1 and 8.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of AEs and SAEs during the study

    Time frame: During entire length of study

Secondary outcomes

  1. To evaluate the difference in treatment with ALD518 relative to treatment with placebo in the proportion of patients achieving a 20% improvement in ACR response (ACR20) at Week 12

    Time frame: 12 weeks after Dose 1

07

Study locations

26 sites
  • K-W Musculoskeletal Research, Inc.
    Kitchener, Ontario N2M 5N6, Canada
  • Rheumatology Research Associates
    Ottawa, Ontario KIH IA2, Canada
  • V. Tsitlanadze Scientific Practical Centre of Rheumatology
    Tbilisi, 0102, Georgia
  • Medulla Chemotherapy and Immunotherapy Clinic
    Tbilisi, 0186, Georgia
  • Chanre Rheumatology and Immunology Center and Research
    Malleshwaram, Bangalore 560 003, India
  • KLE Society Hospital and Medical Research Centre
    Nehru Nagar, Belgaum 590 010, India
  • Sushrut Hospital, Research Centre & Post Graduate Institute of Orthopaedics
    Ramadaspeth, Nagpur 440 010, India
  • St. John's Medical College Hospital
    Bangalore, 560 034, India
  • Krishna Institute of Medical Sciences Ltd.
    Secunderabad, 500 003, India
  • Miriada Center Private Clinic of Professor Sierakowski
    Bialystok, 15-297, Poland
  • Nonpublic Centre of Medical Care Reumed
    Lublin, 26-607, Poland
  • NOVAMED - Medical Center of Poznan
    Poznan, 60-773, Poland
  • Provincional Rheumatological Complex named after Dr Jadwiga Titz-Kosko
    Sopot, 81-759, Poland
  • Szezecin Clinic of Rheumatology and Internal Diseases
    Szczecin, 71-252, Poland
  • Regional Clinical Hospital of War Veterans
    Kemerovo, 650099, Russian Federation
  • Institute of Clinical and Experimental Lymphology
    Novosibirsk, 630117, Russian Federation
  • Ryazan Regional Clinical Cardiologic Dispensary
    Ryazan, 390026, Russian Federation
  • City Hospital #26
    Saint Petersburg, 196247, Russian Federation
  • Saint Petersburg Medical Academy of Postgraduate Study
    Saint-Petersburg, 191015, Russian Federation
  • Saint-Petersburg State Medical Academy named after I. I. Mechnikov
    Saint-Petersburg, 195067, Russian Federation
  • Regional War Veterans' Hospital
    Saratov, 410002, Russian Federation
  • Tomsk Regional Clinical Hospital
    Tomsk, 634063, Russian Federation
  • Tula Regional Clinical Hospital
    Tula, 300053, Russian Federation
  • Clinical Hospital of Emergency Care named after N.V. Solovyev
    Yaroslavl, 150003, Russian Federation
  • Institute of Rheumatology
    Belgrade, 11000, Serbia
  • Institute for Rehabilitation and Treatment Niska Banja
    Niska Banja, 18205, Serbia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Jun 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2009
First posted
Mar 23, 2009
Start
Oct 2008
Primary completionActual
Jun 2009
CompletionActual
Dec 2009
Last update
Jul 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00867516
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Mar 23, 2009
Start date
Oct 2008
Primary completion
Jun 2009
Completion
Dec 2009
Last update
Jul 9, 2020

Study contacts

Jeffrey Smith, MD, FRCP
study director · Alder BioPharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clazakizumab

Start the discussion